VBViktoria Blumenberg

Viktoria Blumenberg

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Viktoria Blumenberg has a total of 380 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Prophylactic IFN-γ blockade drives axi-cel expansion without preventing refractory toxicities: caution against pre-emptive use

    by Viktoria Blumenberg, David J. Bozym, Maxx King, Marisa G. Ogier, Deshea L. Harris, Keshav Sridharan, Jing Li, Patrick C. Johnson, Benjamin R. Puliafito, Alexandra M. Haugh, et al.

    Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) affect most patients receiving axicabtagene ciloleucel (axi-cel) for relapsed or refractory large B-cell lymphoma (LBCL). Based on pre-clinical data, we hypothesized that prophylactic IFN-γ blockade could prevent toxicity without impairing efficacy. We initiated an open-label phase 2 trial (NCT06550141) evaluating single-dose emapalumab one day before axi-cel. Here, we report the first two patients to caution against the pre-emptive emapalumab use prior axi-cel: Both developed treatment-refractory toxicities including high-grade ICANS and overlapping CRS-IEC-HS requiring multiple immunomodulatory agents. CAR T-cell expansion exceeded levels reported in ZUMA-1 and a standard-of-care axi-cel cohort at our institution. Despite therapeutic emapalumab and suppressed free IFN-γ, IL-2 and sIL-2R were markedly elevated, suggesting CRS was driven independent of IFN-γ. Both patients achieved complete responses, suggesting preserved efficacy. Given the unanticipated severity and refractoriness of toxicities, recruitment with this design was discontinued and the protocol was amended.

  • Open Access

    Gene regulatory elements determine efficacy of BCMA-targeted CAR-T cell products

    by Viktoria Blumenberg, Kristen B June, Filippo Birocchi, Giulia Escobar, Charlotte Graham, Yueyang Fan, Merle K Phillips, Sangwoo Park, Deshea Harris, Henry Anderson, et al.

    In relapsed/refractory multiple myeloma, the approved B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor (CAR)-T cell product ciltacabtagene autoleucel (cilta-cel) shows higher response rates than idecabtagene vicleucel (ide-cel) in pivotal trials and real-world comparisons. This advantage has been attributed to the biparatopic dual-VHH (dVHH) binder of cilta-cel. However, the products also differ in the gene regulatory elements driving CAR expression: cilta-cel uses a human elongation factor α (EF1α) promoter in conjunction with a woodchuck hepatitis post-transcriptional regulatory element (EF1α +WPRE ), whereas ide-cel uses a myeloproliferative sarcoma virus enhancer (MND) promoter without WPRE (MMD -WPRE ). The role of these elements in CAR-T cell efficacy remains unexplored. We generated lentiviral vectors where the CAR transgene was composed of either a dVHH-based or a single-chain variable fragment (scFv)-based BCMA-CAR with a 4-1BB costimulatory and a CD3ζ signaling domain, expressed either by EF1α +WPRE or MND -WPRE . Primary human T cells or a nuclear factor of activated T cells (NFAT)-GFP Jurkat reporter line were compared at matched vector copy numbers (VCN) or CAR surface expression. Antitumor efficacy was assessed in MM.1S-engrafted NSG mice. When transduced at the same multiplicities of infection, MND -WPRE CAR-T cells reached higher VCN and transduction rates than EF1α +WPRE regardless of the binder type. In an NFAT-GFP reporter assay, unstimulated MND -WPRE -driven cells showed higher NFAT and CD69 expression, consistent with greater tonic signaling compared with EF1α +WPRE . In vivo, independently of the BCMA binder moiety, EF1α +WPRE -driven CAR-T cells demonstrated superior cytokine secretion and tumor control along with greater survival of mice treated with EF1α +WPRE compared with MND -WPRE -driven CAR-T cells. CAR-T cells expressing the CAR under MND -WPRE showed greater gene transfer during manufacturing, but this did not translate into superior function in vivo. The advantage attributed to cilta-cel’s dual VHH binder was lost when expressed under MND -WPRE and, conversely, ide-cel’s scFv binder achieved better antitumor activity when expressed under EF1α +WPRE than under MND -WPRE . The efficacy difference between our CAR constructs in xenograft models therefore tracked with the choice of regulatory elements driving CAR expression independently of the binder. It may be better to choose gene regulatory elements based on the CAR-T cell function they confer rather than on expression strength alone.

  • Rational Engineering of Notch1 Signaling to Boost the Proliferation of CD19-BBζ CAR-T

    by Merle Kincaid Phillips, Filippo Birocchi, Felix Korell, Diego Salas-Benito, Viktoria Blumenberg, Giulia Escobar, Amanda A Bouffard, Magdi Elsallab, Yueyang Fan, Hana N Takei, et al.

    CAR T-cells targeting CD19 have revolutionized the treatment of relapsed/refractory B-cell malignancies. However, approximately 50% of patients relapse. Patient-derived data indicates that CD19+ relapse is linked to poor CAR T-cell proliferation and/or persistence. We aimed to improve CD19-CAR T-cell survival by manipulating Notch1, a receptor that is activated following T-cell receptor ligation and is essential for upregulating pro-inflammatory and survival genes in T-cells. However, its role in the context of CAR T-cells remains poorly understood. We found that both lentiviral overexpression of Notch1's intracellular domain (N1ICD) and Notch1 genetic knockout resulted in defective CAR-T cell activation and proliferation. This suggests that CAR T-cells require a precise, balanced level of Notch1 signaling for strong effector function. The PEST domain, located at the most distal C-terminus of the Notch1 intracellular domain, regulates the receptor's half-life through ubiquitylation. To augment the levels of active Notch1 and prolong the receptor's signaling, we genetically deleted this domain in the endogenous N1ICD of CAR T-cells. Notch1 PEST-deleted CAR T-cells showed enhanced proliferation post-activation, leading to increased cytotoxicity against CD19+ tumors in vitro. Transcriptionally, Notch1 PEST deletion resulted in upregulation of interferon response pathways and proliferative genes during CAR activation, consistent with Notch1 activation. In B-ALL xenograft in vivo models, treatment with Notch1 PEST-deleted CAR T-cells resulted in greater tumor reduction and increased CAR-T expansion compared to control CAR T-cells. Our findings demonstrate a critical role of Notch1 in CAR-T effector function and provide a novel strategy to augment endogenous Notch1 activity by leveraging native gene regulation.

  • Open Access

    Navigating clinical decision-making for IEC-enterocolitis

    by Viktoria Blumenberg, Mark B. Leick

  • Open Access

    Expert Panel Review and Practical Guidance on Biomarker Testing with Engineered Immune Effector Cells

    by Viktoria Blumenberg, Caroline Diorio, Jordan Gauthier, Jennifer E. Agrusa, Alexandra Dreyzin, Gerulf Hänel, Manuel R. Espinoza-Gutarra, Marcus Geer, Miguel-Angel Perales, Sneha Ramakrishna, et al.


  • Top Cited Papers

    Ruxolitinib for ciltacabtagene autoleucel–associated refractory diarrhea

    by Viktoria Blumenberg, Filippo Birocchi, Angela Shih, Giulia Escobar, Adele Mucci, Alexander Armstrong, Diana Cirstea, Deshea L. Harris, David J. Bozym, Benjamin R. Puliafito, et al.

    Intractable diarrhea is a recently described complication following B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma with reported mortality rates of 36% to 50%. The optimal clinical management is unknown. Here, we report a series of 5 patients who presented with severe diarrhea after BCMA CAR T-cell treatment. We hypothesized that the Janus kinase inhibitor, ruxolitinib, might be an effective therapy based on its success in graft-versus-host-disease after allogeneic bone marrow transplant and other immune-driven diarrhea syndromes. Three patients received ruxolitinib, all of whom experienced rapid clinical improvement. Among the 2 patients with matched pretreatment and posttreatment biopsies, both showed signs of histopathologic response, including 1 with CAR T-cell–associated indolent T-cell lymphoproliferative disease of the gastrointestinal tract.


  • Open Access

    When CAR T cells become the disease

    by Viktoria Blumenberg, Marcela V. Maus

    In this issue of Blood, Hosoya et al1 report a case of premalignant chimeric antigen receptor (CAR) T cells coexpressing the gut-homing integrin receptor α


  • Open Access

    Supplementary Figures from Influence of Adipose Tissue Distribution, Sarcopenia, and Nutritional Status on Clinical Outcomes After CD19 CAR T-cell Therapy

    by Kai Rejeski, David M. Cordas dos Santos, Nathan H. Parker, Veit L. Bücklein, Michael Winkelmann, Khushali S. Jhaveri, Lian Liu, Paul Trinkner, Sophie Günther, Philipp Karschnia, et al.

  • Open Access

    Supplementary Tables from Influence of Adipose Tissue Distribution, Sarcopenia, and Nutritional Status on Clinical Outcomes After CD19 CAR T-cell Therapy

    by Kai Rejeski, David M. Cordas dos Santos, Nathan H. Parker, Veit L. Bücklein, Michael Winkelmann, Khushali S. Jhaveri, Lian Liu, Paul Trinkner, Sophie Günther, Philipp Karschnia, et al.

  • Open Access

    Data from Influence of Adipose Tissue Distribution, Sarcopenia, and Nutritional Status on Clinical Outcomes After CD19 CAR T-cell Therapy

    by Kai Rejeski, David M. Cordas dos Santos, Nathan H. Parker, Veit L. Bücklein, Michael Winkelmann, Khushali S. Jhaveri, Lian Liu, Paul Trinkner, Sophie Günther, Philipp Karschnia, et al.

    Although CD19-directed chimeric antigen receptor T-cell therapy (CD19.CAR-T) has proven clinical efficacy for multiple refractory B-cell malignancies, over 50% of patients ultimately relapse. Recent evidence has underlined the critical role of the host in determining treatment responses. In this retrospective observational study of 106 patients with relapsed/refractory large B-cell lymphoma receiving standard-of-care CD19.CAR-T, we analyzed the impact of immunometabolic host features and detailed body composition measurements on post–CAR T clinical outcomes. We extracted muscle and adipose tissue distributions from prelymphodepletion CT images and assessed laboratory-based immuno-nutritional scores. Early responders displayed increased total abdominal adipose tissue deposits (TAT: 336 mm3 vs. 266 mm3, P = 0.008) and favorable immuno-nutritional scores compared to nonresponding patients. On univariate Cox regression analysis, visceral fat distribution, sarcopenia, and nutritional indices significantly impacted both progression-free (PFS) and overall survival (OS). Patients with a low skeletal muscle index (SMI; e.g.<34.5), a sarcopenia indicator, exhibited poor clinical outcomes (mOS 3.0 months vs. 17.6 months, log-rank P = 0.0026). Prognostically adverse immuno-nutritional scores were linked to inferior survival [low PNI: HROS, 6.31; 95% confidence interval (CI), 3.35–11.90; P < 0.001]. In a multivariable analysis adjusting for baseline Eastern Cooperative Oncology Group performance status, C-reactive protein, and lactate dehydrogenase, increased TAT was independently associated with improved clinical outcomes (adjusted HROS, 0.27; 95% CI, 0.08–0.90; P = 0.03). We noted particularly favorable treatment outcomes in patients with both increased abdominal fat and muscle mass (TAThigh/SMIhigh: 1-year PFS 50%, 1-year OS 83%). These real-world data provide evidence for a role of body composition and immuno-nutritional status in the context of CD19.CAR-T and suggest that the obesity paradox may extend to modern T cell–based immunotherapies.See related Spotlight by Nawas and Scordo, p. 704